dacarbazine / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dacarbazine / Generic mfg.
2016-000317-78: Comparison of PV-10 to Chemotherapy or Oncolytic Viral Therapy for Treatment of Malignant Melanoma of the Skin Confronto tra PV-10 verso chemioterapia o terapia virale oncolitica per il trattamento del melanoma cutaneo localmente avanzato

Not yet recruiting
3
225
Europe
PV-10, Temozolomide, Dacarbazine, Temodal 20 mg capsule rigide, Temodal 100 mg capsule rigide, Temozolamide, TEMODAL, NA, Suspension for injection, Powder for solution for injection, Capsule, hard, Solution for injection, DACARBAZINA MEDAC - 200 MG POLVERE PER SOLUZIONE INIETTABILE O PER INFUSIONE 10 FLACONCINI IN VETRO, Temodal 5 mg capsule rigide, Imlygic 10^6 plaque forming units (PFU)/mL solution for injection, DACARBAZINA MEDAC - 500 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO, TEMODAL - 20 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 100 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 140 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 180 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 250 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, Imlygic 10^8 plaque forming units (PFU)/mL solution for injection
PROVECTUS BIOPHARMACEUTICALS, INC., Provectus Biopharmaceuticals, Inc
Locally Advanced Cutaneous Melanoma Melanoma cutaneo localmente avanzato, Malignant melanoma of skin Melanoma maligno della pelle, Diseases [C] - Cancer [C04]
 
 
ECHELON-1 , NCT01712490 / 2011-005450-60: A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Checkmark Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Jul 2022 - Jul 2022: Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Checkmark Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
May 2022 - May 2022: Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
Checkmark Five year data from ECHELON-1 study for advanced classical Hodgkin lymphoma at ASH 2020
More
Active, not recruiting
3
1334
Europe, Canada, Japan, US, RoW
brentuximab vedotin, ADCETRIS®, SGN-35, doxorubicin, Adriamycin, bleomycin, vinblastine, dacarbazine, DTIC
Takeda, Seagen Inc.
Hodgkin Lymphoma
04/17
01/26
2019-003014-13: Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. Intérêt de la chimiothérapie péri-opératoire chez les patients porteurs de sarcomes des tissus mous localisés de grade 1 ou 2, définis à HAUT RISQUE par la signature CINSARC.

Not yet recruiting
3
600
Europe
DOXORUBICIN, IFOSFAMIDE, DACARBAZINE, Solution for infusion, Powder for solution for injection, Powder for solution for infusion
INSTITUT CLAUDIUS REGAUD, Direction Générale de l’Offre de Soins (DGOS)
Soft Tissue Sarcoma Sarcome des tissus mous, Soft Tissue Sarcoma Sarcome des tissus mous, Diseases [C] - Cancer [C04]
 
 
APROMISS, NCT03016819 / 2017-001655-31: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma

Active, not recruiting
3
325
Europe, US, RoW
AL3818, Catequentenib, Anlotinib, Dacarbazine, DTIC, AL3818 or placebo
Advenchen Laboratories, LLC
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
12/24
06/25
SEACRAFT-2, NCT06346067: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma

Recruiting
3
470
US
Naporafenib, ERAS-254, LXH254, Dacarbazine, DTIC, Temozolomide, Temodar, TMZ, Trametinib, Mekinist
Erasca, Inc.
Advanced or Metastatic NRAS-mutant Melanoma
04/28
12/28
CIRSARC, NCT03805022: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Recruiting
3
165
RoW
tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
Shanghai Kechow Pharma, Inc.
Melanoma
09/27
09/27
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
SUNRISELMS, NCT05269355: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics
Leiomyosarcoma
06/24
06/24
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28

Download Options